
Former England fast bowler David Lawrence dead at 61
A statement from Lawrence's family given to Britain's PA news agency said: "It is with great sadness that we announce the passing of Dave Lawrence MBE following his brave battle with motor neurone disease."
Lawrence bagged a five-wicket haul against the West Indies in 1991 to help England seal a series-levelling win at the Oval, with Desmond Haynes and Vivian Richards among the batsmen he dismissed.
But his career all but ended the following year with a sickening injury when he shattered his kneecap running into bowl during a Test against New Zealand in Wellington.
That was the end of his time with England, although he made a brief comeback for Bristol-based Gloucestershire, playing four four-first class games in 1997 before retiring for good after taking 625 wickets for the county.
He later became president of Gloucestershire, with his old county saying in a social media post Sunday that they were "devastated" to learn of Lawrence's death.
Following his MND diagnosis, there were emotional scenes when Gloucestershire won the T20 Blast final at Edgbaston last year, with captain James Bracey presenting the trophy to Lawrence.
His MND diagnosis also hastened Lawrence's autobiography amid fears he would lose the ability to speak.
Titled 'In Syd's Voice', and written with the help of cricket journalist Dean Wilson, the book was published this month.
England and Wales Cricket Board chairman Richard Thompson hailed Lawrence as a "true trailblazer" who became a "powerful voice for inclusion and representation in our sport".
There was a minute's applause in honour of Lawrence before the start of the third day's play in the first Test between England and India at Headingley on Sunday, with players and officials also wearing black armbands as a mark of respect.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fashion Network
5 hours ago
- Fashion Network
Crystal Palace Football Club and Macron extend partnership
Italian sportswear designer/provider Macron has signed a new multi-year contract extension with English Premier League club Crystal Palace. With the south London club having won the FA Cup in May and now set to play in one of Europe's key knockout competitions for the 2025/26 season, the contract expansion is a certainly a key one for Macron. It continues 'the strong and successful relationship between the club and the Italian brand leader in sportswear', the Bologna-based company said. It noted that the 'now-iconic FA Cup-winning shirt', has been officially restocked and will be distributed to fans starting from mid-September (priced £70), and will include the return of its historic 1861 crest. The extended agreement will also see Macron continue to supply all match day kits, training wear, travel-wear and accessories for players and fans. 'Preparations are already under way for future collections that combine high-performance materials, stylish design and a deep connection to the club's heritage', it also said. Crystal Palace commercial director Barry Webber added: 'Macron has proven to be a fantastic partner for Crystal Palace, and this renewal is a natural next step in what has been a hugely successful collaboration. 'Together we've produced some of the most memorable kits in the club's modern history, and this new agreement builds on everything we've achieved so far.' Macron CEO Gianluca Pavanello also said: 'This year, we experienced one of the most thrilling moments in Crystal Palace's history, and we are glad to have been a part of it. We are equally delighted to continue this successful journey together and to celebrate future victories on the pitch.'


Fashion Network
5 hours ago
- Fashion Network
Crystal Palace Football Club and Macron extend partnership
Italian sportswear designer/provider Macron has signed a new multi-year contract extension with English Premier League club Crystal Palace. With the south London club having won the FA Cup in May and now set to play in one of Europe's key knockout competitions for the 2025/26 season, the contract expansion is a certainly a key one for Macron. It continues 'the strong and successful relationship between the club and the Italian brand leader in sportswear', the Bologna-based company said. It noted that the 'now-iconic FA Cup-winning shirt', has been officially restocked and will be distributed to fans starting from mid-September (priced £70), and will include the return of its historic 1861 crest. The extended agreement will also see Macron continue to supply all match day kits, training wear, travel-wear and accessories for players and fans. 'Preparations are already under way for future collections that combine high-performance materials, stylish design and a deep connection to the club's heritage', it also said. Crystal Palace commercial director Barry Webber added: 'Macron has proven to be a fantastic partner for Crystal Palace, and this renewal is a natural next step in what has been a hugely successful collaboration. 'Together we've produced some of the most memorable kits in the club's modern history, and this new agreement builds on everything we've achieved so far.' Macron CEO Gianluca Pavanello also said: 'This year, we experienced one of the most thrilling moments in Crystal Palace's history, and we are glad to have been a part of it. We are equally delighted to continue this successful journey together and to celebrate future victories on the pitch.'


France 24
6 hours ago
- France 24
The big business behind weight-loss drugs: Global market to hit $150 billion by 2035
12:43 Issued on: 12:43 min They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive big pharma's revenue for years to come. But they come with a hefty price tag, while some 50 to 70 percent of people taking GLP-1s suffer side effects. Charles Pellegrin asks Frederic Bizard, a health economist and professor at ESCP Business School, who has the most to gain from this pharma revolution.